MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2023-24)
- Udyam number
- UDYAM-TS-02-0021350
Market Cap
₹170 Cr
OXYGENTAPH · BSE
Share Price
₹48.00
+4.19% today
Revenue
₹113 Cr
FY 2025-26 · +3.4% YoY
EBITDA
−₹15.32 Cr
Margin -13.6%
Net Profit
−₹17.56 Cr
FY 2025-26 · -69.7% YoY
Authorised capital
₹37.5 Cr
Registered with MCA
Paid-up capital
₹36.98 Cr
Issued & subscribed
Open charges
₹46.6 Cr
Satisfied ₹55.7 Cr
About Oxygenta Pharmaceutical Limited
Data last updated:
Oxygenta Pharmaceutical Limited is a public limited company based in Medak, Telangana, India. It operates in the organic chemicals and compounds segment of the chemicals and materials sector. It was incorporated on 27 November 1990 and has been in existence for over 36 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24110TG1990PLC012038. Its GSTIN is 36AADCS2216C1ZW (Telangana). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 524636.
The company has an authorised share capital of ₹37.5 Cr and a paid-up capital of ₹36.98 Cr. It was formerly known as S.S. Organics Pvt Ltd and S.S. Organics Ltd. It is led by directors including Chandra Mouliswar Reddy Gangavaram (Whole-Time Director) and Balasubba Reddy Mamilla (Whole-Time Director).
Its last annual general meeting (AGM) was held on 19 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Survey No.252/1 Aroor Village Sadasivapet Mandal Medak District, Telangana, India.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹112.98 Cr, a growth of 3.4% compared to the previous year. For the same year it recorded a net loss of ₹17.56 Cr (net margin -15.5%) and EBITDA of -₹15.32 Cr (EBITDA margin -13.6%). Total assets are valued at ₹67.86 Cr (up 80.1% YoY).
The company has about 98 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Oxygenta Pharmaceutical Ltd and S S Organics. As per MCA filings, the company has open charges of ₹46.6 Cr and satisfied charges of ₹55.7 Cr on record. Court records list 90 cases involving the company, including 32 filed by the company and 58 filed against it; 3 cases are pending. The company has 13 deals on record (10 market trades, 2 secondary share transfers, 1 funding round), with disclosed funding of ₹4 Cr; the latest was in February 2026.
Oxygenta Pharmaceutical Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0021350). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website oxygentapharma.com.
Company details
CIN L24110TG1990PLC012038
Registration Number 012038
Incorporation Date 27 November 1990
ROC Hyderabad
Listing Status Listed - Listed on BSE (524636)
Company Status Active
Date of Last AGM 19 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-02-0021350
Name history
Oxygenta Pharmaceutical has undergone 2 name changes throughout its history. The company was previously known as S.S. Organics Pvt Ltd, and S.S. Organics Ltd.. The current legal name is Oxygenta Pharmaceutical Limited.
| Company Name | Status |
|---|---|
| Oxygenta Pharmaceutical Limited | Current |
| S.S. Organics Pvt Ltd | Previous |
| S.S. Organics Ltd. | Previous |
CIN history
Oxygenta Pharmaceutical has one previous CIN (Corporate Identification Number): L24110AP1990PLC012038. The current CIN is L24110TG1990PLC012038, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1990PLC012038 | Current |
| L24110AP1990PLC012038 | Previous |
Key People
Chandra Mouliswar Reddy Gangavaram Whole-Time Director Balasubba Reddy Mamilla Whole-Time Director Vedavathi Gangavaram Director Recognitions & Rankings of Oxygenta Pharmaceutical
Contact details
Oxygenta Pharmaceutical Limited's registered office is in Medak, Telangana. Its website is oxygentapharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressSurvey No.252/1 Aroor Village Sadasivapet Mandal Medak District, Telangana, India
- IndustryChemicals and Materials, Organic Chemicals & Compounds
To see the full contact details of Oxygenta Pharmaceutical Limited, buy the company report.
Comprehensive company report
Oxygenta Pharmaceutical Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Oxygenta Pharmaceutical operates two associated brands: Oxygenta Pharmaceutical Ltd and S S ORGANICS. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Finished products and APIs are manufactured for therapeutic categories. | ssorganics.co.in | |
| Manufacturing of drugs, pharmaceutical preparations, and organic fine chemicals in India. | oxygentapharma.com |
Financials of Oxygenta Pharmaceutical Limited
FY 2025-26 filings availableOxygenta Pharmaceutical Limited reported revenue of ₹112.98 Cr (up 3.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹113 Cr
+3.4% YoY
EBITDA
−₹15.32 Cr
-56.0% YoY
Profit After Tax
−₹17.56 Cr
-69.7% YoY
Net Worth
−₹42.69 Cr
-66.5% YoY
Total Assets
₹67.86 Cr
+80.1% YoY
Total Debt
₹110 Cr
+76.1% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 113 | 109 | 39.64 | 30.99 | 60.52 | 52.03 | 13.72 |
| Revenue growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| EBITDA | (15.32) | (9.82) | (9.71) | (7.97) | 0.67 | 3.85 | (7.86) |
| EBITDA margin | -13.6% | -9.0% | -24.5% | -25.7% | +1.1% | +7.4% | -57.3% |
| Profit before tax | (22.17) | (14.35) | (13.86) | (11.37) | (0.48) | 3.15 | (5.93) |
| Net profit | (17.56) | (10.35) | (3.51) | (10.85) | (1.03) | 0.90 | (9.77) |
| Net profit margin | -15.5% | -9.5% | -8.9% | -35.0% | -1.7% | +1.7% | -71.2% |
| EPS (₹) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Balance sheet | |||||||
| Total assets | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Net worth | (42.69) | (25.64) | (20.13) | (46.20) | (34.63) | (38.02) | (40.95) |
| Total debt | 110 | 62.23 | 57.23 | 68.00 | 52.13 | 47.89 | 26.92 |
| Cash & bank | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Net working capital | (0.40) | (14.20) | (1.35) | (2.13) | 2.58 | 1.29 | (8.72) |
| Cash flow | |||||||
| Cash from operations | (27.75) | 2.83 | (13.05) | (1.63) | (1.68) | (1.62) | (2.59) |
| Cash from investing | (14.39) | (11.32) | (4.09) | (9.64) | (4.94) | (6.72) | (0.50) |
| Cash from financing | 42.56 | 8.49 | 17.13 | 11.22 | 6.33 | 8.67 | 3.19 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.00 | 49.61 | 33.93 | 14.30 | 15.13 | 49.47 | 33.21 | 14.01 |
| Revenue growth (YoY) | +144.6% | +0.3% | +2.2% | +2.1% | +19.9% | - | - | - |
| Other income | 0.02 | 0.17 | 0.00 | (0.06) | 0.17 | 0.05 | 0.49 | 0.75 |
| Total expenses | 36.45 | 49.50 | 38.01 | 18.88 | 21.98 | 51.42 | 37.56 | 16.18 |
| EBITDA | 0.55 | 0.11 | (4.08) | (4.58) | (6.85) | (1.95) | (4.35) | (2.17) |
| EBITDA margin | +1.5% | +0.2% | -12.0% | -32.0% | -45.3% | -3.9% | -13.1% | -15.5% |
| Depreciation | 0.62 | (0.24) | 0.86 | 0.86 | 0.85 | (0.23) | 0.71 | 0.66 |
| Interest | 2.46 | 1.81 | 1.39 | 0.95 | 0.63 | 2.13 | 0.39 | 0.69 |
| Profit before tax | (2.51) | (1.29) | (6.33) | (6.45) | (8.16) | (3.80) | (4.96) | (2.77) |
| Tax | (0.40) | 0.42 | (1.48) | (1.51) | (2.04) | (1.65) | (1.03) | 0.08 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.00 | 49.61 | 33.93 | 14.30 | 15.13 | 49.47 | 33.21 | 14.01 |
| Revenue growth (YoY) | +144.6% | +0.3% | +2.2% | +2.1% | +19.9% | - | - | - |
| Other income | 0.02 | 0.17 | 0.00 | (0.06) | 0.17 | 0.05 | 0.49 | 0.75 |
| Total expenses | 36.45 | 49.50 | 38.01 | 18.88 | 21.98 | 51.42 | 37.56 | 16.18 |
| EBITDA | 0.55 | 0.11 | (4.08) | (4.58) | (6.85) | (1.95) | (4.35) | (2.17) |
| EBITDA margin | +1.5% | +0.2% | -12.0% | -32.0% | -45.3% | -3.9% | -13.1% | -15.5% |
| Depreciation | 0.62 | (0.24) | 0.86 | 0.86 | 0.85 | (0.23) | 0.71 | 0.66 |
| Interest | 2.46 | 1.81 | 1.39 | 0.95 | 0.63 | 2.13 | 0.39 | 0.69 |
| Profit before tax | (2.51) | (1.29) | (6.33) | (6.45) | (8.16) | (3.80) | (4.96) | (2.77) |
| Tax | (0.40) | 0.42 | (1.48) | (1.51) | (2.04) | (1.65) | (1.03) | 0.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 113 | 109 | 39.64 | 30.99 | 60.52 | 52.03 | 13.72 |
| Revenue growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| Other income | 0.29 | 1.31 | 0.10 | 0.14 | 1.36 | 2.28 | 4.02 |
| Total expenses | 128 | 119 | 49.35 | 38.96 | 59.85 | 48.18 | 21.58 |
| Employee cost | 7.61 | 6.76 | 5.96 | 5.74 | 0.58 | 4.08 | 2.50 |
| EBITDA | (15.32) | (9.82) | (9.71) | (7.97) | 0.67 | 3.85 | (7.86) |
| EBITDA margin | -13.6% | -9.0% | -24.5% | -25.7% | +1.1% | +7.4% | -57.3% |
| Depreciation | 2.32 | 3.61 | 2.66 | 2.05 | 1.59 | 1.20 | 1.00 |
| Interest | 4.82 | 2.23 | 1.59 | 1.49 | 0.92 | 1.78 | 1.09 |
| Profit before tax | (22.17) | (14.35) | (13.86) | (11.37) | (0.48) | 3.15 | (5.93) |
| Tax | (4.61) | (4.05) | (10.39) | 0.20 | 0.12 | 0.21 | (0.15) |
| Net profit | (17.56) | (10.35) | (3.51) | (10.85) | (1.03) | 0.90 | (9.77) |
| Net profit margin | -15.5% | -9.5% | -8.9% | -35.0% | -1.7% | +1.7% | -71.2% |
| EPS (₹) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 36.98 | 36.98 | 33.48 | 14.20 | 14.20 | 10.20 | 10.20 |
| Reserves & surplus | (79.67) | (62.62) | (54.17) | (60.40) | (48.83) | (48.22) | (51.15) |
| Shareholders' funds (net worth) | (42.69) | (25.64) | (20.13) | (46.20) | (34.63) | (38.02) | (40.95) |
| Secured loans | 43.11 | 13.92 | 10.86 | 41.99 | 33.86 | 2.85 | 0.50 |
| Unsecured loans | 66.45 | 48.31 | 46.37 | 26.01 | 18.27 | 45.04 | 26.42 |
| Total debt | 110 | 62.23 | 57.23 | 68.00 | 52.13 | 47.89 | 26.92 |
| Total liabilities | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Assets | |||||||
| Gross block | 74.58 | 61.49 | 50.53 | 46.43 | 36.44 | 31.18 | 25.10 |
| Net block | 47.60 | 36.83 | 29.35 | 27.91 | 19.98 | 16.31 | 11.42 |
| Capital work in progress | 0.00 | 0.23 | 0.00 | 0.00 | 0.34 | 0.65 | 0.00 |
| Investments | 0.47 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Inventories | 29.42 | 20.51 | 13.72 | 11.71 | 7.28 | 12.11 | 4.25 |
| Sundry debtors | 10.03 | 5.10 | 7.36 | 10.16 | 1.58 | 1.61 | 0.42 |
| Cash & bank balances | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Loans & advances | 9.83 | 5.21 | 2.93 | 3.04 | 0.55 | 1.77 | 1.98 |
| Total current assets | 51.43 | 30.94 | 24.11 | 25.02 | 9.57 | 15.94 | 6.77 |
| Total current liabilities | 51.83 | 45.14 | 25.46 | 27.15 | 6.99 | 14.65 | 15.49 |
| Net working capital | (0.40) | (14.20) | (1.35) | (2.13) | 2.58 | 1.29 | (8.72) |
| Total assets | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.00 | 0.00 | 0.11 | 0.16 | 0.45 | 0.12 | 0.02 |
| Net cash from operating activities | (27.75) | 2.83 | (13.05) | (1.63) | (1.68) | (1.62) | (2.59) |
| Net cash from investing activities | (14.39) | (11.32) | (4.09) | (9.64) | (4.94) | (6.72) | (0.50) |
| Net cash from financing activities | 42.56 | 8.49 | 17.13 | 11.22 | 6.33 | 8.67 | 3.19 |
| Net change in cash | 0.42 | 0.00 | (0.01) | (0.05) | (0.29) | 0.33 | 0.10 |
| Closing cash | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| EBITDA growth | -56.0% | -1.1% | -21.8% | -1289.6% | -82.6% | +149.0% | - |
| PBT growth | -54.5% | -3.5% | -21.9% | -2268.8% | - | +9998.0% | -69.4% |
| Net income growth | -69.7% | -194.9% | +67.7% | -953.4% | -214.4% | +109.2% | - |
| Revenue CAGR (3Y) | +53.9% | +21.8% | -8.7% | +31.2% | +43.4% | +59.3% | +19.0% |
| EBITDA CAGR (3Y) | +24.3% | - | - | +0.5% | - | - | +17.5% |
| Profitability & leverage | |||||||
| Net income margin | -15.5% | -9.4% | -8.8% | -37.3% | -1.0% | +5.7% | -42.1% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +7.9% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -5.8% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -27.32 | -16.60 | -12.85 | -14.87 | -100.00 | 67.17 | -12.30 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.66 | 1.95 | 0.82 | 0.75 | 1.79 | 1.85 | 0.55 |
| Inventory turnover | 4.53 | 6.39 | 3.12 | 3.26 | 6.24 | 6.36 | 2.86 |
| Debtors turnover | 14.93 | 17.54 | 4.53 | 5.28 | 37.94 | 51.26 | 29.51 |
| EPS (₹) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | (11.54) | (6.93) | (6.18) | (32.53) | (24.38) | (37.27) | (40.14) |
To see the full year-wise statements and ratios of Oxygenta Pharmaceutical Limited, buy the company report.
Board of directors of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical has 8 current directors and 41 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vedavathi Gangavaram Also directs: Virupaksha Life Sciences LLP, Virupaksha Minerals LLP, Virupaksha Organics Limited and 3 more | Director | 20 Jun 2025 | 1 Years 4 Months | Current |
| Veera Reddy Arava Also directs: Virupaksha Organics Limited | Director | 20 Jun 2025 | 1 Years 4 Months | Current |
| Sidda Reddy Kanuparthi Also directs: Virupaksha Organics Limited, Kanuparthi Trading LLP, Harinandan Enterprises Private Limited and 1 more | Director | 20 Jun 2025 | 1 Years 4 Months | Current |
| Sharvari Swapnil Shinde | Director | 20 Jun 2025 | 1 Years 4 Months | Current |
| Chandra Mouliswar Reddy Gangavaram Also directs: Virupaksha Life Sciences LLP, Virupaksha Minerals LLP, Virupaksha Organics Limited and 3 more | Whole-Time Director | 20 Jun 2025 | 1 Years 4 Months | Current |
| Balasubba Reddy Mamilla | Whole-Time Director | 20 Jun 2025 | 1 Years 4 Months | Current |
Showing 6 of 8 current directors. View all directors
Auditor
Oxygenta Pharmaceutical Limited is audited by Gowri Shankar and associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Gowri Shankar and associates | FY 2023 | 015625S |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 56.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 43.50%.
Sep 2026
QUARTER
56.50% Promoters
43.50% Retail & Others
Promoter holding - history
Now 56.50% · Sep 2026High 58.00% · Dec 2025Low 55.90% · Mar 2026
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 56.50% | 56.50% | 55.90% | 58.00% |
| Public | 43.50% | 43.50% | 44.10% | 42.00% |
Charges & borrowings
Open charges
₹46.6 Cr
Satisfied charges
₹55.7 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Jun 2025 | 101130641 | Others | ₹46.6 Cr | Open | |
| 02 Sep 2022 | 100607294 | Others | ₹5 Cr | Satisfied | |
| 02 Sep 2022 | 100607750 | Others | ₹10 Cr | Satisfied | |
| 21 Dec 2020 | 100396266 | Others | ₹6.7 Cr | Satisfied | |
| 10 Sep 2020 | 100377137 | Others | ₹31.5 Cr | Satisfied |
To see the full charge records of Oxygenta Pharmaceutical Limited, buy the company report.
Total charge records: 6 View all charges
Deals & funding
Oxygenta Pharmaceutical Limited has 13 deals on record (10 market trades, 2 secondary share transfers, 1 funding round), with disclosed funding of ₹4 Cr; the latest was in February 2026.
Total deals
13
Market trades
10
Secondary share transfers
2
Funding round
1
Disclosed funding
₹4 Cr
Deals on record (5 of 13)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2026 | Market trade | ₹1.41 Cr | Buyer: Virupaksha Organics Limited Seller: an individual |
| Dec 2025 | Market trade | ₹1.11 Cr | Buyer: Virupaksha Organics Limited Seller: an individual |
| Aug 2021 | Funding round | ₹4 Cr | |
| Sep 2019 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Others - S S Organics Ltd |
| Dec 2007 | Market trade | ₹17.1 Lakh | Seller: Regal Corporate Advisors Private Limited |
To see the full deal history of Oxygenta Pharmaceutical Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Oxygenta Pharmaceutical Limited has 90 court cases on record: 32 filed by Oxygenta Pharmaceutical, 58 filed against it. 3 cases are pending and 87 are disposed.
Total cases
90
Filed by the company
32
Filed against the company
58
Pending
3
Disposed
87
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 50 | 45 | 0 |
| High courts | 37 | 12 | 2 |
| Supreme Court | 2 | 0 | 0 |
| NCLAT | 1 | 1 | 1 |
Cases on record (5 of 90)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Hyderabad CCC, Telangana | Criminal complaint | Filed against the company by Aurobindo Pharma Ltd | Disposed |
| High Court, TELANGANA | Writ petition | Filed by the company against The Bombay Stock Exchange Ltd., and 4 others | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Civil suit | Filed against the company by Ms. Mangalam Drugs and Organics Ltd Th. Mr. Ashish Arvindbhai Shah | Disposed |
| District court, Hyderabad CCC, Telangana | Petition | Filed by the company against Ms Aurobindo Pharma Ltd. | Disposed |
| High Court, TELANGANA | Arbitration matter | Filed by the company against M/S. Aurobindo Pharma Ltd., and 1 other | Disposed |
To see the full case history of Oxygenta Pharmaceutical Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Oxygenta Pharmaceutical Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Oxygenta Pharmaceutical Limited has a workforce of 98 employees on its EPFO records as of Sep 11, 2024, across 1 active EPFO establishment.
Employee count
98
Active EPFO establishments
1
Employee growth
-4.85%
GST
Oxygenta Pharmaceutical has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AADCS2216C1ZW | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Oxygenta Pharmaceutical Limited, buy the company report.
Recent activity
Oxygenta Pharmaceutical Limited has 73 board changes on record since 2006: 41 appointments and 32 cessations. The latest: Amireddy Venkatesu Reddy was appointed as Additional Director on 23 May 2026.
Appointed
Amireddy Venkatesu Reddy was appointed as Additional Director.
Appointed
Janardhana Reddy Yeddula was appointed as Additional Director.
Filing
Oxygenta Pharmaceutical Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Appointed
Prasad Reddy Battinapatla was appointed as CFO.
Charges
A charge registered on 10 Sep 2020 via Charge ID 100377137 with Others was fully satisfied on 26 Nov 2025.
Charges
A charge with Others of Rs. 46.60 Cr registered on 30 Jun 2025 with Charge ID 101130641 was modified on 30 Sep 2025.
AGM
Oxygenta Pharmaceutical Limited last Annual general meeting of members was held on 19 Sep 2025 as per latest MCA records.
Ceased
Sanagari Kondal Reddy ceased to be Director.
Ceased
Vankineni Sai Sudhakar ceased to be Managing Director.
Charges
A charge registered on 02 Sep 2022 via Charge ID 100607294 with Others was fully satisfied on 07 Aug 2025.
Charges
A charge registered on 02 Sep 2022 via Charge ID 100607750 with Others was fully satisfied on 07 Aug 2025.
Charges
A charge with Others amounted to Rs. 46.60 Cr with Charge ID 101130641 was registered on 30 Jun 2025.
77 earlier events are in the company report.
News
Frequently asked questions
Oxygenta Pharmaceutical is an active public limited company based in Medak, Telangana, India. The company works in organic chemicals and compounds, within the chemicals and materials industry. It was incorporated on 27 November 1990 (36+ years old) and is registered under CIN L24110TG1990PLC012038. Listed on BSE: 524636.
Oxygenta Pharmaceutical reported revenue of ₹112.98 Cr for FY 2025-26 (up 3.4% YoY) based on standalone financials.
Oxygenta Pharmaceutical has 8 current directors:
- Chandra Mouliswar Reddy Gangavaram - Whole-Time Director
- Balasubba Reddy Mamilla - Whole-Time Director
- Vedavathi Gangavaram - Director
- Veera Reddy Arava - Director
- Sidda Reddy Kanuparthi - Director
- Sharvari Swapnil Shinde - Director
- Janardhana Reddy Yeddula - Additional Director
- Amireddy Venkatesu Reddy - Additional Director
The latest financial statements of Oxygenta Pharmaceutical on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 19 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Oxygenta Pharmaceutical is 36AADCS2216C1ZW, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Oxygenta Pharmaceutical is L24110TG1990PLC012038. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Oxygenta Pharmaceutical is a listed company as per MCA records. Its shares are listed on BSE (code: 524636).
Oxygenta Pharmaceutical has 90 court cases on record: 32 filed by the company and 58 filed against it. 3 are pending. Most are in the district courts.
Oxygenta Pharmaceutical was incorporated on 27 November 1990, making it 36+ years old. It is registered with the Registrar of Companies, Hyderabad.
Oxygenta Pharmaceutical has 13 deals on record (10 market trades, 2 secondary share transfers, 1 funding round), with disclosed funding of ₹4 Cr; the latest was in February 2026.